← All trials
NCT06569953
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 26, 2024
- Primary completion
- Aug 31, 2025
- Completion date
- Aug 31, 2025
- First posted
- Aug 26, 2024
- Last posted
- Sep 26, 2024
- Enrollment
- 284
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Chongqing Medical UniversityLead sponsor
- Central South UniversityCollaborator
- Chongqing Medical UniversityOfficial
- Chongqing Medical UniversityCollaborator
- LanZhou UniversityCollaborator
- People's Hospital of ChongqingCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.